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Objectives: Conventional magnetic resonance imaging (MRI) is used to diagnose and monitor inﬂammatory
disease in relapsing remitting (RR) multiple sclerosis (MS). In the less common primary progressive (PP) form
of MS, in which focal inﬂammation is less evident, biomarkers are still needed to enable evaluation of novel
therapies in clinical trials. Our objective was to characterize the association— across the brain and cervical spinal
cord— between clinical disability measures in PPMS and two potential biomarkers (one for myelin, and one for
atrophy, both resulting from the same imaging technique).
Methods:Multi-component driven equilibrium single pulse observation of T1 and T2 (mcDESPOT) MRI of the
brain and cervical spinal cord were obtained for 15 PPMS patients and 11matched controls. Data were analysed
to estimate the signal related to myelin water (VFM), as well as volume measurements. MS disability was
assessed using theMultiple Sclerosis Functional Composite score, which includes measures of cognitive process-
ing (Paced Auditory Serial Addition Test), manual dexterity (9-Hole Peg Test) and ambulatory function (Timed
25-Foot Walk); and the Expanded Disability Status Scale.
Results: Brain and spinal cord volumes were different in PPMS compared to controls, particularly ventricular
(+46%, p = 0.0006) and cervical spinal cord volume (−16%, p = 0.0001). Brain and spinal cord myelin (VFM)
were also reduced in PPMS (brain:−11%, p = 0.01; spine:−19%, p= 0.000004). Cognitive processing cor-
related with brain ventricular volume (p = 0.009). Manual dexterity correlated with brain ventricular volume
(p = 0.007), and both brain and spinal cord VFM (p = 0.01 and 0.06, respectively). Ambulation correlated
with spinal cord volume (p = 0.04) and spinal cord VFM (p = 0.04).
Interpretation: In this study we demonstrated that mcDESPOT can be used tomeasuremyelin and atrophy in the
brain and spinal cord. Results correlate well with clinical disability scores in PPMS representing cognitive, ﬁne
motor and ambulatory disability.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
In 10–20% of cases, multiple sclerosis (MS) presents with progres-
sive development of disability from onset (primary progressive (PP)
MS), differentiating it from the more common relapsing–remitting
(RR) form of the disease. Although it is not believed to be a separate dis-
order (Antel et al., 2012), none of the current therapies used to treat
RRMS have been found to be effective in PPMS (Kantarci, 2013). The
identiﬁcation of an effective therapy for PPMS has been hindered by
the lack of a sufﬁciently sensitive biomarker to evaluate a therapeutic
effect in early phase clinical trials. There is therefore an urgent need
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for methods that can better monitor PPMS disease progression to assist
in the development of disease modifying drugs and for incorporation
into clinical trials (Rice et al., 2013).
Atrophy occurs early in MS (De Stefano et al., 2001; Sastre-Garriga
et al., 2005a; Tiberio et al., 2005) and has beenmeasured in all MS phe-
notypes (De Stefano et al., 2010; Grassiot et al., 2009; Pagani et al., 2005;
Tedeschi et al., 2005), with PPMS showing greater and earlier spinal
cord atrophy than RRMS (Bieniek et al., 2006; Lukas et al., 2013). Atro-
phy of the brain and cervical spinal cord correlate with clinical scores
and appear to be good biomarkers for disability; they have also been
demonstrated to be reliable measures for assessing disease progression
(Bieniek et al., 2006; Chard et al., 2004; Grassiot et al., 2009; Lukas et al.,
2013; Sastre-Garriga et al., 2005b; Tiberio et al., 2005). Cervical cord
volume (CCV) has been shown to decrease signiﬁcantly over two
years in PPMS, demonstrating potential utility within the timeframe of
most clinical trials (Laule et al., 2010).
While atrophy measurements are clearly sensitive and relevant to
MS progression, they are unspeciﬁc. It is also important to differentiate
between contributing pathological processes, including inﬂammation,
axonal damage, and particularly, myelin damage, as these may distin-
guish between differentMS subtypes and provide a greater understand-
ing of disease pathogenesis and treatment effect.
Multi-component relaxation imaging is a sensitive and speciﬁc MRI
technique for measuring changes in myelin. This approach separates
MR (magnetic resonance) signal into that originating from different
water environments, based on relaxation characteristics; water in
intra/extracellular spaces relaxes more slowly than water trapped be-
tween myelin sheaths (MacKay et al., 1994). Multi-component driven
equilibrium single pulse observation of T1 & T2 (mcDESPOT) consists
of a series of spoiled gradient echo (SPGR) and balanced steady state
free precession (SSFP) images, each acquired over a range of ﬂip angles.
The variousﬂip angles provide an assortment of different contrasts with
varying degrees of T1- and T2-weighting. It can be used to estimate the
fraction of signal from each water pool, in particular, the fraction of
faster-relaxing signal of water associated with myelin, the myelin
water volume fraction (VFM) (Deoni, 2011; Deoni et al., 2008). Previous
studies have demonstrated reduced VFM in PPMS brain (Kolind et al.,
2012), and robust results in healthy cervical spinal cord (Kolind and
Deoni, 2011). Beneﬁcially, the images that make up the mcDESPOT ac-
quisition can also be assessed as standard structural images. An SPGR
scan with a ﬂip angle of 18° provides excellent contrast for assessment
of brain and spinal cord volume. Thus our protocol can be used to simul-
taneously assess atrophy andVFM, both ofwhich appear to be important
in PPMS.
In this study, we applied a mcDESPOT protocol to measure atrophy
and VFM in PPMS brain and spinal cord, comparing results with those
from matched healthy controls as well as with clinical measures of
disability. The goal was to demonstrate the applicability of mcDESPOT
to the study of PPMS and its potential for use in future clinical trials of
disease modifying therapies.
2. Materials and methods
2.1. Subject information
The study was ethically reviewed and given a favourable opinion,
under the UK's Health Research Authority, by the South East
Coast—Surrey Research Ethics Committee (REC reference: 11/LO/0739).
Appropriate approvals were also obtained from the King's College
NHS Foundation Trust, through which patients were recruited. In-
formed consent was obtained from all participants. Fifteen subjects
with clinically deﬁned PPMS fulﬁlling the 2005 revised McDonald
criteria for diagnosis (Polman et al., 2005): 11 males, mean age 52
(range 41–67) years; median Expanded Disability Status Scale
(EDSS) = 5.0 (2.5–6.5); mean disease duration = 6 (2-17) years;
mean brain lesion volume = 19 (0–61) cm3; mean number of spinal
cord lesions = 4 (2-6) were recruited and compared to 11 age and
gender-matched healthy controls (9 males, mean age 49 (range 37–64)
years).
Disability was assessed for the MS subjects using EDSS (Kurtzke,
1983) and the Multiple Sclerosis Functional Composite (MSFC) score
(Fischer et al., 1999), which includes measures of cognitive processing
(Paced Auditory Serial Addition Test; PASAT), manual dexterity
(9-Hole Peg Test; 9HPT) and ambulatory function (Timed 25-Foot
Walk; T25FW).
2.2. Image acquisition
Brain:MR image acquisition was performed on a 1.5 T GE Signa sys-
tem (General Electric, Waukesha, USA). mcDESPOT data were acquired
sagittally over the whole brain, with a 1.7 mm isotropic voxel size;
SPGR: TE/TR = 1.9/5 ms, 8 optimised ﬂip angles up to 18°; SSFP:
TE/TR = 1.8/3.6 ms, 8 optimised ﬂip angles up to 70°, phase-cycling
pattern = 0° and 180° (for correction of off-resonance effects); total
scan time 10 min (Deoni et al., 2008). Axial FLAIR and PD/T2-weighted
images were also collected for lesion identiﬁcation (total 7 min).
Spinal Cord: mcDESPOT data were acquired sagittally over the
entire cervical spinal cord (ﬁeld of view (FOV) = 20 cm) with
0.78(A/P) × 0.78(A/P) × 1 mm(S/I) voxel size; SPGR: TE/TR =
2.2/4.9 ms, 8 optimised ﬂip angles up to 18°; inversion recovery
prepared SPGR (IRSPGR): TE/TR = 2.05/4.9 ms, α= 5°, TI = 350 ms
(for correction of B1 inhomogeneity effects (Deoni, 2011)); SSFP:
TE/TR = 1.6 ms/3.2 ms, 8 optimised ﬂip angles up to 70°, phase-
cycling pattern = 0° and 180°; total scan time 24 min (Kolind and
Deoni, 2011). Sagittal T1-weighted and T2-weighted and axial
multiple-echo recombined gradient echo (“MERGE”) images were
also collected for lesion identiﬁcation (total 15.5 min).
2.3. Image analysis
Volume measurements: Both brain and cervical spinal cord volume
measurements were calculated using one of the 3D T1-weighted SPGR
scans from the mcDESPOT data (ﬂip angle = 18°).
Brain volume measurements:Whole-brain, peripheral and total grey
matter, whitematter and ventricular cerebrospinal ﬂuid (vCSF) volume
were calculated using the FSL tool Structural Image Evaluation using
Normalisation of Atrophy (SIENAX) (Smith et al., 2002). First, lesions
were manually delineated by an experienced neuroradiologist on the
PD images and linearly registered to the SPGR. Within SIENAX, brain
and skull images are extracted and afﬁne registered to the Montreal
Neurological Institute 152 standard image. Tissue-type segmentation
is then carried out, taking the lesion masks as input to ensure correct
classiﬁcation of white matter voxels with altered intensities. A back-
normalised standard space mask is used to isolate peripheral (i.e. corti-
cal) from total GM, which also includes subcortical structures. Finally,
SIENAX produces tissue-class-speciﬁc volumes normalised for head
size, using a scaling factor derived from the registration.
Spinal cord volume measurements: Cervical cord area was computed
from 13 slices at the C2/C3 intervertebral disc using a modiﬁed version
of the semi-automatic method by Tench et al. (Tench et al., 2005). The
algorithm is a region-growing technique that uses edge detection, par-
tial volume estimation and cord angle correction to ensure accuracy.
VFM measurements: VFM maps were calculated voxelwise using a
three-pool mcDESPOT analysis approach (Deoni et al., 2013). White
matter was extracted using FSL-FAST. Regions of interest in the corpus
callosum and minor forceps were selected based on previous results
showing correlation between VFM and the mental functional system
EDSS score in these regions (Kolind et al., 2012). These regions of inter-
est were generated from the JHU atlases in FSL, manually edited to re-
move regions of partial volume, and analysed in native space. Spinal
cord tissue was extracted (over the whole cervical cord from C1 to C7)
using FSL-FAST, and manually edited to remove regions of partial
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volume. Mean VFM values were calculated for all white matter, the cor-
pus callosum, minor forceps, and whole cervical cord. Two controls
were excluded from the VFM spinal cord analysis. One could not ﬁt
comfortably into the neck coil, and the other had substantial motion
artefact; there was still no signiﬁcant age difference between groups
after excluding these participants.
Statistics: Non-parametric statistics were performed to compare
volume measurements and VFM values between PPMS and controls
(Mann–Whitney U-test), and to correlate volume measurements and
VFM values with clinical scores (Spearman's rank test). As this was an
exploratory study applying a new method, and because many of our
measures may be correlated with each other, we did not apply a strict
correction for multiple comparisons. Instead, we carefully selected
(and minimized) the tests to be performed, and report uncorrected
p-values for these tests so that readers can appreciate the likely degree
of signiﬁcance whether or not corrections for multiple comparisons
were performed.
3. Results
3.1. Volume differences
Brain and spinal cord volume was signiﬁcantly reduced in PPMS
subjects in comparison to controls (an example is shown in Figs. 1
and 2a–e).
Compared to controls, PPMS subjects had larger CSF volumes (vCSF;
on average +46%, p = 0.0006, Fig. 2a), and smaller total grey matter
(−7%, p = 0.005, Fig. 2b), peripheral grey matter (−6%, p = 0.01,
Fig. 2c), whole-brain (−5%, p = 0.02, Fig. 2d) and white matter
(−3%, p = 0.07, Fig. 2e) volume. Cervical spinal cord volume was also
16% lower than healthy controls (p = 0.0001, Fig. 2f).
3.2. Myelin water volume fraction differences
Global normal appearing white matter VFM was reduced in PPMS
subjects compared to control normal white matter (−11%, p = 0.01,
Fig. 3a) as well as for the individual structures of the minor forceps
(−16%, p = 0.01, Fig. 3b) and corpus callosum (−29%, p = 0.0008,
Fig. 3c). VFM was also decreased by 19% in the cervical spinal cord of
PPMS subjects compared to controls (p = 0.000004, Fig. 3d).
3.3. Comparison with clinical scores
Table 1 reports Spearman rank correlation coefﬁcients (R) and
p-values for correlations between the MR metrics and clinical scores.
VFM for total white matter, and for the minor forceps, were excluded
from the table as no signiﬁcant relationships were found.
The brain atrophy measure, vCSF, correlated with the overall MSFC
score (R = −0.73, p = 0.002) as well as with the cognitive subtest,
PASAT (R = −0.65, p = 0.009) and the manual dexterity test, 9HPT
(R = −0.67, p = 0.007), but not with the ambulatory function,
T25FW (R = 0.075, p = 0.8) nor EDSS (R = 0.231, p = 0.4). PPMS
CCV correlated with the T25FW (R = −0.54, p = 0.04) but did not
reach signiﬁcance with EDSS (R =−0.47, p = 0.08).
The corpus callosum VFM correlated with the 9HPT (R = 0.64, p =
0.01) with a trend towards signiﬁcance with EDSS (R = −0.50, p =
0.06). The VFM of the cervical spinal cordwas related to themost clinical
scores, showing correlations with EDSS (R =−0.53, p = 0.04), MSFC
(R = 0.57, p = 0.03) and T25FW (R =−0.53, p = 0.04) with a trend
towards signiﬁcance with 9HPT (R = 0.49, p = 0.06).
3.4. Comparison between volume and VFM
Across all participants, therewas a correlation between CCV andVFM
(R = 0.56, p = 0.005). When separated into controls or PPMS, there
were no correlations (controls: R =−0.08, p = 0.8; PPMS: R = 0.21,
p = 0.5). Similarly in brain, there was a weak correlation between
vCSF and global normal appearing white matter VFM (R = −0.45,
p = 0.02) that was not present for controls alone (R = −0.34, p =
0.3) nor PPMS alone (R =−0.27, p = 0.3).
4. Discussion
There is currently no effective treatment for PPMS, as detailed in the
recent review by Ontaneda et al. (Ontaneda et al., 2015). Development
of therapies has been hindered by the lack of an effective imaging out-
come for clinical trials; in RRMS, gadolinium enhancing and new T2 le-
sions on conventional MRI can be used. Advanced MRI may provide
sensitive and speciﬁc measures to meet this challenge in PPMS. While
atrophy measurements demonstrate sensitivity to volume loss over
time in PPMS, they are unspeciﬁc. The relative contributions of water,
myelin or axon loss to volume changes is not equal across all types of
MS, all patients, or even all lesions. For example, in a pathological
study of spinal cord, Tallantyre et al. (Tallantyre et al., 2009) demon-
strated more extensive reduction of axonal density in demyelinated re-
gions in PPMS than in secondary progressive MS, with less
inﬂammatory activity. Myelin loss in MS could be due to inﬂammatory
demyelination, or Wallerian degeneration leading to loss of axons and
theirmyelin sheaths.While demyelination itselfmaynot be the primary
driver of chronic disease progression or disability, being able to differen-
tiate between areas of inﬂammation, edema, demyelination, axonal loss
and remyelination would be invaluable to determining such important
factors as the likelihood of repair of a region, or the relative axon loss to
myelin loss. Thus a measurement providing sensitive measures of vol-
ume combined with a speciﬁc marker for myelin would be extremely
valuable.
The most commonly used advanced MRI measurements related to
myelin are magnetization transfer imaging and diffusion tensor imaging,
both of which have revealed differences between PPMS and healthy con-
trols in the brain and spinal cord. Magnetization transfer (MT) imaging
provides estimates of macromolecular-bound water, which have been
shown to be associated with myelin in histopathological studies, albeit
with mixed results (reported R2 values with myelin stain include 0.2
(van Waesberghe et al., 1997), 0.42 (Mottershead et al., 2003), 0.58
(Bot et al., 2004) and 0.80 (Schmierer et al., 2007)). It should be noted
that MT effects have been shown to be strongly inﬂuenced by inﬂamma-
tion in animal models (Gareau et al., 2000; Serres et al., 2009). In
Fig. 1. Illustrative case of atrophy in both brain and spinal cord for a subject with PPMS
(age 54, EDSS 6.0) compared to a control (age 58).
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postmortemMS brain, no signiﬁcant difference between active and in-
active lesionswas found inMT nor any other quantitativeMRI or histol-
ogy indices, suggesting inﬂammationmay interfere to a lesser degree in
the association between myelin and MT than in animal models
(Schmierer et al., 2007). However, in vivo studies have demonstrated
a strong link between MT and total water content, advocating that
results should be interpreted with caution (Fox et al., 2005; van
Waesberghe et al., 1997; Vavasour et al., 2011).
Diffusion tensor imaging, while exquisitely sensitive to the micro-
structural architecture, reﬂects not only myelin, but also ﬁbre coherence,
axonal density, and membrane permeability (Beaulieu, 2002; Harsan
et al., 2006).
Fig. 2. Bar charts illustrating the difference in volume between control (blue) and PPMS (red) brain and spinal cord; speciﬁcally (a) ventricular volume, vCSF, (b) grey matter volume,
(c) peripheral grey matter volume, (d) total brain volume, (e) white matter volume and (f) cervical spinal cord volume, CCV. The mean percent difference and p-value are noted, with
signiﬁcant differences (p b 0.05) indicated in bold.
Fig. 3. Bar charts illustrating the difference in mcDESPOT myelin water volume fraction, VFM, between control (blue) and PPMS (red) brain and spinal cord regions; speciﬁcally (a) all
(normal-appearing)whitematter, (b)minor forceps, (c) corpus callosumand (d) all cervical spinal cord. Themeanpercent difference andp-value are noted (allwere signiﬁcant, p b 0.05).
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Multi-component relaxation imagingmay be themost sensitive and
speciﬁc MRI technique for measuring changes in myelin. Preclinical
(Kozlowski et al., 2008; McCreary et al., 2009; Odrobina et al., 2005;
Stanisz et al., 2004; Webb et al., 2003) and postmortem human studies
(Laule et al., 2006, 2008) have demonstrated strong correlations be-
tween histological measures of myelin and the myelin water fraction
measurement provided by multi-component relaxation imaging.
mcDESPOT (Deoni et al., 2008) provides a rapid, high-volumetric cover-
age approach to multi-component relaxation imaging that makes this
technique a viable option for clinical trials.
In this study, the utility of mcDESPOT, which produces quantitative
measurements of brain and spinal cord myelin contents in addition to
volume, was examined in relation to commonly used clinical measures
of disability formonitoring PPMS. This study demonstrated that cervical
spinal cord myelin water volume fraction is signiﬁcantly reduced in
PPMS compared to controls, corresponding well with post mortem
studies (Gilmore et al., 2005). PPMS whole brain and regional white
matter also had decreased VFM that correlatedwith disability, indicating
that diffusewhitematter damage is an important pathological feature in
PPMS that can be monitored with mcDESPOT.
The cohortwas small for this study, thus correlationswith clinical in-
dices should be interpreted with caution. However, taken concurrently,
the brain and spinal cord atrophy and VFM measurements came neatly
together to describe the studied aspects of clinical disability. (1) Cogni-
tion: declining cognitive scores were largely represented by brain vol-
ume changes. (2) Dexterity: reduced dexterity was reﬂected by
reduced brain volume, but more speciﬁcally, by reduced VFM in both
corpus callosum and spinal cord. (3) Ambulation: ambulationwas relat-
ed to reduced spinal cord volume, likely demyelination (as indicated by
VFM) in particular.
vCSF correlated with both the PASAT and 9HPT scores, while the
more speciﬁc corpus callosum VFM was only related to the 9HPT. This
result may suggest that the PASAT score is more closely associated
with decreases in whole brain volume rather than white matter myelin
content while the manual dexterity task deﬁcits were more inﬂuenced
by demyelination in important pathways.
For the ambulatory task, the T25FW was negatively correlated with
both spinal cord CCV (implicating atrophy) and VFM (implicating mye-
lin loss). Interestingly, spinal cord VFM also had a trend to correlate with
the 9HPT (R = 0.49, p = 0.06) while CCV did not (R = 0.11, p = 0.7).
While the ambulation scores correlated with both CCV and spinal
cord VFM, they are not redundant measures. Across all participants,
there was a signiﬁcant correlation between CCV and VFM (R = 0.56,
p = 0.005), thus reductions in VFM account for roughly 30% of the var-
iance in CCV. This correlationwas largely bimodal; i.e. control and PPMS
data were well separated in the correlation plots, rather than forming
part of a continuum; the correlation was driven by the inter-group
differences (in both scores) between the groups, with no signiﬁcant
intra-group differences between CCV and VFM (controls: R =−0.08,
p = 0.8; PPMS: R = 0.21, p = 0.5). A similar effect was seen in brain,
with a weak correlation between vCSF and global normal appearing
white matter VFM (R =−0.45, p = 0.02 for all participants, dropping
to−0.34 (p = 0.3) for controls and−0.27 (p = 0.3) for PPMS). Thus
while a substantial reduction inmyelin is reﬂected by a decrease in vol-
ume, only 20–30% of the change in volume is a reﬂection of the change
in VFM; volume changes also reﬂect other tissue or water loss. Thus VFM
and volume are complementarymeasures; by obtainingVFM in addiction
to measuring volume we are gleaning more speciﬁc information about
what is driving atrophy. In addition, spinal cord VFM correlated more
strongly with the overall disabilitymeasures andwas linked to the dex-
terity task, and therefore may be more clinically relevant than CCV.
Measuring both volume and VFM could therefore aid in targeting thera-
pies and monitoring progression more effectively. Fig. 4 illustrates the
utility of spinal cord VFM for rapid assessment of myelin changes in
the spinal cord; for the age-matched healthy control the VFM values
are visibly higher, while the conventional images do not demonstrate
the changes apparent in the PPMS VFM image.
Table 1
Spearman rank correlation coefﬁcients between MR measures and clinical scores.
Brain
Volume
Brain
VFM
Spinal cord Volume Spinal cord
VFM
vCSF Corpus callosum CCV Whole cervical cord
EDSS R = 0.23, p = 0.4 R =−0.50, p = 0.06 R =−0.47, p = 0.08 R =−0.53, p = 0.04
MSFC R =−0.73, p = 0.002 R = 0.46, p = 0.09 R = 0.45, p = 0.09 R = 0.57, p = 0.03
PASAT R =−0.65, p = 0.009 R = 0.11, p = 0.7 R = 0.16, p = 0.6 R = 0.33, p = 0.2
9HPT R =−0.67, p = 0.007 R = 0.64, p = 0.01 R = 0.11, p = 0.7 R = 0.49, p = 0.06
T25FW R = 0.08, p = 0.8 R =−0.40, p = 0.1 R =−0.54, p = 0.04 R =−0.53, p = 0.04
Signiﬁcant relationships (p b 0.05) indicated in bold, and trends (p = 0.06) in italics.
9HPTwas measured as the average of the inverse of the time for the dominant hand and the inverse of the time for the non-dominant hand (thus 9HPT score decreases for longer times),
and T25FW was measured as the average time over 2 attempts (thus T25FW score increases for longer times).
Fig. 4. Illustrative case of spinal cord pathology evident for a subject with PPMS (age 58,
EDSS 6.5) compared to a control (age 58). The same colour scale was used for both partic-
ipants. While 2 lesions were noted within the PPMS cervical spinal cord by a neuroradiol-
ogist (NS), markedly lower mcDESPOT VFM values are apparent throughout the PPMS
spinal cord (particularly in anterior regions); the T1- and T2-weighted images do not re-
ﬂect this diffuse pathology.
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Volume measurements in the brain (Shiee et al., 2012) and spinal
cord (Bieniek et al., 2006; Laule et al., 2010) were in line with literature
reports, indicating that the images from the mcDESPOT acquisition are
well suited to this analysis. Using a standard protocol across centres
for atrophy measurements as part of a mcDESPOT imaging protocol
would improve consistency of atrophy results for multi-centre trials.
The traditional approach to multi-component relaxation imaging
(multiple spin-echo T2 relaxation) has not previously been applied to
study brain in a cohort of people with PPMS. The more recently intro-
duced approach of mcDESPOT has been applied in PPMS brain (Kolind
et al., 2012), revealing reduced VFM in PPMS compared to controls, and
demonstrating correlations with EDSS functional subscores. The results
from the present study were consistent with those past results, but pro-
vide further detail with the inclusion of the MSFC and its components.
Traditionalmulti-component relaxation imaging has been applied to
PPMS spinal cord (Laule et al., 2010), however the reduction in myelin
water fraction in PPMS compared to controls did not reach signiﬁcance
(12% reduction, p= 0.09, 20 PPMS and 24 healthy controls). Laule et al.
did however detect a signiﬁcant reduction in PPMS spinal cord myelin
water fraction over 2 years (−10.5%, p = 0.01). In the current study,
using mcDESPOT, we successfully detected a reduction in VFM between
PPMS and controls (19%, p = 0.000004, 15 PPMS and 9 healthy
controls). The increased signiﬁcance in this study is likely due to the
smaller inter- and intra-subject coefﬁcient of variation for mcDESPOT
measures of VFM compared to traditional myelin water fraction mea-
surements (Kolind and Deoni, 2011). It is therefore very encouraging
that mcDESPOT spinal cord VFM measurements will be sensitive to
changes over time and able to detect treatment effects with relatively
small cohorts.
While atrophy has been proven to be relevant to disease progression
and is known to differ between PPMS and controls, it lacks speciﬁcity. A
marker related to myelin provides further information on what is
driving the atrophy and may be more sensitive in a case with oppos-
ing pathologies. For instance, upon commencement of therapy,
pseudoatrophy (reduction in brain volume due to resolution of
inﬂammation) is common. A ﬁnding of atrophy in the absence of a
decrease in VFM may elucidate the difference between an effective
or detrimental intervention.
Despite the small cohort, the results of this study clearly demon-
strate the ability of mcDESPOT to distinguish between PPMS and
healthy controls, and the clinical relevance of the calculated measures.
This quantitative measurement is equally applicable at other ﬁeld
strengths, across centres, system manufacturers, and over time (Deoni
et al., 2009; Kolind et al., 2012, 2013), providing a robust method for
assessing patients consistently. mcDESPOT is also more time efﬁcient
than traditional spin-echo based multi-component relaxation tech-
niques, covering the entire brain at 1.7 mm-slice thickness or cervical
spinal cord at 1 mm-slice thickness compared to only between 1 and
20 5 mm-slices in similar time with traditional approaches (MacKay
et al., 1994; MacMillan et al., 2011; Minty et al., 2009; Prasloski et al.,
2012; Wu et al., 2006). Perhaps more important will be the investiga-
tion of whether the measured values reﬂect clinical changes over
time, through longitudinal studies.
5. Conclusions
In summary, mcDESPOT acquisition forwhole brain and cervical spi-
nal cord differentiated between PPMS and healthy controls, and provid-
ed a comprehensive description of clinical scores in this cohort. Brain
volume was linked to scores for cognitive processing and manual dex-
terity, and spinal cord volume to ambulation. VFM in brain correlated
with manual dexterity, while in the cervical spinal cord it correlated
with all clinical scores except cognitive processing. Volume measure-
ments and VFM were not strongly correlated, and thus are likely sensi-
tive to different processes. Together, these measurements provide
complementary information, with increased speciﬁcity for myelin
provided by VFM. This protocol promises to present a full picture of pro-
gression in PPMS and provide effective measures in clinical trials for
therapeutic treatment of progression.
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